← All trials
NCT06291948
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Jan 10, 2023
- Completion date
- Oct 20, 2023
- First posted
- Mar 4, 2024
- Last posted
- Mar 4, 2024
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Richmond LaboratoriesLead sponsor
- FP Clinical Pharma S.R.L.Official
- FP Clinical Pharma S.R.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.